In addition, Lifileucel (Amtagvi, United States, approved in February 2024), a tumor-infiltrating lymphocyte therapy containing autologous T-cells harvested from the patient’s own tumor and expanded ex vivo, is approved by the FDA for treating adults with unresectable or metastatic melanoma, another solid tumor cancer, in those previously treated with PD-1 inhibitors and, if applicable, BRAF/MEK inhibitors [14]. Here, MAP2K7 is linked to neoplasm.